Skip to main content
    S

    Scilex Holding Company (SCLX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $2.88
    +0.08 (+2.86%)

    Market Cap: $20.05M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    18%(2/11)
    Avg Surprise
    -2153.28%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 14
    		$-16.65N/AN/ABeat-124.4%
    Mar 26
    Reported Apr 10
    		$-1.17$-0.47-148.94%Miss+32.4%
    Dec 25
    Reported Feb 25
    		$-1.17$-0.47-149.28%Miss+50.6%
    Sep 25
    Reported Nov 14
    		$-21.29$-0.41-5092.68%Miss-1459.7%
    Jun 25
    Reported Aug 13
    		$-7.42$-0.91-715.38%Miss+19.1%
    Mar 25
    Reported May 14
    		$-1.73$-0.01-17200.00%Miss+76.5%
    Dec 24
    Reported Jan 17
    		$-2.37$-3.15+24.76%Beat-848.0%
    Sep 24
    Reported Nov 27
    		$-1.36N/A+61.00%Beat+93.8%
    Jun 24
    Reported Aug 13
    		$-9.17$-4.90-87.14%Miss-40.2%
    Mar 24
    Reported May 13
    		$-7.35$-3.50-110.00%Miss-3240.9%
    Dec 23
    Reported Mar 11
    		$-0.25$-0.23-8.70%Miss-92.3%
    Sep 23
    Reported Nov 14
    		$-22.05$-6.13-259.71%Miss-220400.0%
    Jun 23
    Reported Aug 11
    		$-6.54N/AN/ABeat-5549.7%
    Mar 23
    Reported May 12
    		$-0.22N/AN/ABeat-340.0%
    Dec 22
    Reported Mar 7
    		$-0.13N/AN/ABeat-285.7%
    Sep 22
    Reported Nov 4
    		$-0.01N/AN/ABeat+87.5%
    Jun 22
    Reported Aug 12
    		$0.12N/AN/ABeat+50.0%
    Mar 22
    Reported May 16
    		$-0.05N/AN/ABeat-101.9%
    Dec 21
    Reported Mar 31
    		$0.07N/AN/ABeat-
    Sep 21
    Reported Nov 10
    		$-0.08N/AN/ABeat-
    Jun 21
    Reported Jul 23
    		$0.08N/AN/ABeat-
    Mar 21
    Reported Jun 29
    		$2.70N/AN/ABeat-
    Dec 20
    Reported Mar 30
    		$0.00$0.00N/ABeat-
    Sep 20
    Reported Dec 15
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.07EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-385.00%
    ROE0.00%ROIC143.52%
    Financial Health
    Debt/Equity-0.26xInterest Coverage-17.57x
    Current Ratio0.07xQuick Ratio0.06x
    Trading Statistics
    Beta1.79Avg Volume44.54K
    52-Week High$16.8152-Week Low$2.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.58
    SMA 20$4.28
    SMA 50$5.24
    SMA 200$5.68
    EMA 10$3.48
    EMA 20$4.04
    EMA 50$4.96
    EMA 200$6.02

    MACD

    Line: -0.68Signal: -0.54Hist: -0.14

    ADX

    ADX: 26.6+DI: 15.1-DI: 31.9

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$3.75

    Bollinger Bands

    Upper Band$6.05
    Lower Band$2.52
    %B Position8240%(Upper)
    Band Width0.10

    RSI (14-Day)

    Oversold
    20.3

    Momentum Oscillators

    Stoch %K1.9
    Stoch %D1.9
    Williams %R-96.5
    ROC (10d)-34.7%
    Momentum-1.53
    CCI (20d)-130.0
    MFI (14d)16.1

    Volatility Measures

    ATR (14d)$0.40(13.8%)
    StdDev (20d)0.88
    Hist Vol88.1%(High)

    Volume Flow

    VWAP$2.96
    OBV3.5M
    AD Line179.4M
    CMF (20d)-0.620

    Volume Metrics

    Avg Vol (20d)45.6K
    Vol Ratio0.7x
    VWMA (20d)$3.98

    Pivot Points

    R3$3.05
    R2$3.00
    R1$2.90
    Pivot Point$2.85
    S1$2.75
    S2$2.70
    S3$2.60

    Advanced Oscillators

    TSI-52.89
    Ultimate Osc15.0
    KST-322.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.64M$8.61M$4.79M$10.56M$9.90M$5.00M$14.90M$14.44M$16.37M$10.88M$13.46M$10.12M
    Cost of Revenue$3.68M$4.45M$2.61M$3.33M$3.27M$1.38M$4.69M$3.77M$4.39M$3.84M$4.52M$3.39M
    Gross Profit$3.96M$4.17M$2.18M$7.23M$6.62M$3.62M$10.21M$10.67M$11.98M$7.04M$8.94M$6.72M
    Operating Expenses$33.39M$36.34M$113.27M$193.74M$27.13M$31.52M$38.59M$30.59M$27.60M$26.52M$27.28M$45.53M
    R&D$3.34M$3.21M$8.17M$3.90M$6.19M$2.46M$2.18M$2.35M$2.00M$3.11M$2.73M$4.07M
    SG&A$27.96M$31.03M$30.16M$188.82M$19.84M$28.06M$35.41M$29.73M$24.60M$29.28M$23.52M$40.43M
    Operating Income$-29,423,000$-32,169,000$-111,090,000$-186,512,000$-20,507,000$-27,898,000$-28,378,000$-19,917,000$-15,623,000$-19,478,000$-18,339,000$-38,805,000
    Interest Income$-50,737,000$-31,710,000$0$0$0$0$0$0$0$0$0$0
    Interest Expense$6.10M$3.78M$10.85M$2.80M$2.68M$2.48M$285,000$576,000$571,000$531,000$551,000$513,000
    Income Before Tax$-114,979,000$-45,650,000$-46,099,000$-257,819,000$-44,029,000$-26,080,000$-6,461,000$-4,388,000$-37,582,000$-24,377,000$-21,392,000$-35,529,000
    Income Tax Expense$7,000$0$0$1,000$19,000$0$0$0$0$0$8,000$0
    Net Income$-229,972,000$-45,650,000$-46,105,000$-257,820,000$-88,096,000$-26,080,000$-6,460,000$-4,388,000$-37,582,000$-24,377,000$-21,400,000$-35,529,000
    EBITDA$-54,312,000$-6,265,000$-88,014,000$-253,998,000$-40,337,000$-22,596,000$-4,950,000$-2,776,000$-35,973,000$-22,784,000$-19,776,000$-33,944,000
    EBIT$-58,138,000$-10,162,000$-90,010,000$-255,021,000$-41,347,000$-23,599,000$-6,176,000$-3,812,000$-37,011,000$-23,846,000$-20,841,000$-35,016,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SCLX

    News

    SCLX Forecast — Price Target — Prediction for 2027

    This article provides a financial overview of Scilex Holding Company (SCLX), detailing its current stock price, market capitalization, historical performance...

    TradingView•10/10/26•Somewhat-Bearish

    Scilex Expands Credit Facility Support for Vivasor Affiliate

    Scilex Holding Company has increased its revolving line of credit for its affiliate, Vivasor, Inc., from $20 million to $30 million. This amendment, approved by Scilex's board and audit committee...

    The Globe and Mail•10/1/26•Somewhat-Bullish

    Form 8K Scilex Holding Co For: 29 September By Investing.com

    This article reports that Scilex Holding Co filed a Form 8K on September 29, 2026. The brief announcement provides the filing date for the company's SEC document. The article itself contains minimal textual content...

    Investing.com Canada•9/30/26•Neutral

    Form 8K Scilex Holding Co For: 29 September By Investing.com

    This article reports on the filing of a Form 8K by Scilex Holding Co for September 29. It includes the company's stock information, mentioning a 0.91% increase. The piece also provides a brief overview of market indices...

    Investing.com Nigeria•9/29/26•Neutral

    Form 8K Scilex Holding Co For: 29 September By Investing.com

    This article reports on the filing of a Form 8K by Scilex Holding Co on September 29, 2026. The brief entry provides a direct link to the SEC filing...

    Investing.com South Africa•9/29/26•Neutral

    SCLX Valuation and Fair Value

    P/E
    -0.1x
    Forward P/E
    5.6x
    P/B
    -0.1x
    See GNG's fair value

    SCLX Profitability: Margins, ROIC and FCF

    Gross margin
    55.5%
    Operating margin
    -385.0%
    Net margin
    0.0%
    ROIC
    143.5%
    ROE
    0.0%
    FCF margin
    -64.9%

    SCLX Competitors

    CompanyTicker
    Cocrystal Pharma IncCOCP
    Quoin Pharmaceuticals Ltd DRCQNRX
    PAVmed IncPAVM
    Vyne Therapeutics IncVYNE
    Universe Pharmaceuticals IncUPC
    Entero Therapeutics, Inc.ENTO
    InspireMD IncNSPR
    SeaStar Medical Holding CorporationICU

    Sector: Healthcare

    SCLX Bull Case vs Bear Case

    Bull case

    • SCLX earns a 143.5% return on invested capital.

    Bear case

    • SCLX beat EPS estimates in 25.0% of its last 8 reported quarters.
    • SCLX's quarterly revenue changed -22.8% year over year.

    SCLX Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -872.5%

    Frequently Asked Questions About SCLX

    Does SCLX pay dividends?

    Scilex Holding Company (SCLX) does not currently pay a regular dividend.

    What is SCLX's market cap?

    Scilex Holding Company (SCLX) has a market capitalization of $20.05M with a current stock price of $2.88.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In